TG Therapeutics to Participate in the Cantor Global Healthcare Conference
TG Therapeutics will host a webcast fireside chat with its CEO during the Cantor Global Healthcare Conference on September 9, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
TG Therapeutics (TGTX) will participate in the Cantor Global Healthcare Conference being held September 9–11, 2026. Chairman and CEO Michael S. Weiss is scheduled for a fireside chat on Wednesday, September 9, 2026, at 11:30am ET.
A live webcast will be accessible via the Events page in the Investors & Media section of the company’s website.
Details
News Market Reaction – TGTX
On Sep 3, the day this news came out, TGTX closed 0.33% below the previous close.
Data tracked by StockTitan Argus for the Sep 3 session.
Key Figures
- Conference dates
- September 9–11, 2026
- Cantor Global Healthcare Conference
- Fireside chat time
- 11:30am ET
- Wednesday, September 9, 2026
Historical Context
-
Precision BioSciences data announcement followed by a 0.66% decline
-
Q2 results and raised BRIUMVI guidance followed by an 11.26% decline
-
Conference call scheduling announcement followed by a 2.53% decline
-
Phase 2 schizophrenia trial initiation followed by a 4.05% gain
-
Positive Phase 1 myasthenia gravis data followed by a 5.91% gain
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Fireside chat scheduled for Wednesday, September 9, 2026, at 11:30am ET
NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the Cantor Global Healthcare Conference, being held on September 9 - 11, 2026. The fireside chat is scheduled to take place on Wednesday, September 9, 2026, at 11:30am ET.
A live webcast of the fireside chat will be available on the Events page, located within the Investors & Media section, of the Company’s website at http://ir.tgtherapeutics.com/events.
ABOUT TG THERAPEUTICS
TG Therapeutics is a fully integrated, commercial stage, biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI® (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features. For more information, visit www.tgtherapeutics.com, and follow us on X (formerly Twitter) @TGTherapeutics and on LinkedIn.
BRIUMVI® is a registered trademark of TG Therapeutics, Inc.
CONTACT:
Investor Relations
Email: ir@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 4
Media Relations:
Email: media@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 6
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When is TG Therapeutics (TGTX) presenting at the Cantor Global Healthcare Conference?
TG Therapeutics will participate in the Cantor Global Healthcare Conference taking place September 9–11, 2026. The company’s fireside chat is scheduled for Wednesday, September 9, 2026, at 11:30am ET.
Who will represent TG Therapeutics (TGTX) at the Cantor Global Healthcare Conference fireside chat?
Michael S. Weiss, the Chairman and Chief Executive Officer of TG Therapeutics, will participate in the fireside chat at the Cantor Global Healthcare Conference.
How can investors access the TG Therapeutics (TGTX) fireside chat webcast from the Cantor conference?
A live webcast of the TG Therapeutics fireside chat will be available on the Events page within the Investors & Media section of the company’s website at http://ir.tgtherapeutics.com/events.
What is TG Therapeutics’ main approved product mentioned in the conference announcement for TGTX?
TG Therapeutics highlights BRIUMVI (ublituximab-xiiy), approved by the U.S. FDA to treat adult patients with relapsing forms of multiple sclerosis and also approved by several regulatory agencies outside the U.S. for adults with relapsing multiple sclerosis who have active disease.
How can investors contact TG Therapeutics (TGTX) Investor Relations regarding the conference appearance?
Investors can contact TG Therapeutics Investor Relations by email at ir@tgtxinc.com or by telephone at 1.877.575.TGTX (8489), Option 4.